| Sarah Beth Koenigseker, CNM | |
|
584 Hospital Dr Ne Unit B, Bolivia, NC 28422-0020 | |
| (910) 721-4050 | |
| (910) 721-4051 |
| Full Name | Sarah Beth Koenigseker |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 8 Years |
| Location | 584 Hospital Dr Ne Unit B, Bolivia, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528513223 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | APRN.CNM.19111 (Ohio) | Secondary |
| 367A00000X | Advanced Practice Midwife | 870 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
News Archive
Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
La Jolla Pharmaceutical Company today announced that La Jolla and Adamis Pharmaceuticals Corporation have agreed to terminate their merger agreement relating to the proposed merger of the two companies.
Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system's action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells ("Galectins," Chapter 7, Wiley, 2008).
For people with Down syndrome, news from Elixirgen, LLC may brighten their day. The biotechnology company, located in the Science + Technology Park at Johns Hopkins, has outlined one of the best potential therapies yet for people with Down syndrome and other chromosome disorders in a paper entitled, "Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures," published in the journal DNA Research.
› Verified 8 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
La Jolla Pharmaceutical Company today announced that La Jolla and Adamis Pharmaceuticals Corporation have agreed to terminate their merger agreement relating to the proposed merger of the two companies.
Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system's action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells ("Galectins," Chapter 7, Wiley, 2008).
For people with Down syndrome, news from Elixirgen, LLC may brighten their day. The biotechnology company, located in the Science + Technology Park at Johns Hopkins, has outlined one of the best potential therapies yet for people with Down syndrome and other chromosome disorders in a paper entitled, "Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures," published in the journal DNA Research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Beth Koenigseker, CNM Po Box 60447, Charlotte, NC 28260-0447 Ph: (910) 721-4050 | Sarah Beth Koenigseker, CNM 584 Hospital Dr Ne Unit B, Bolivia, NC 28422-0020 Ph: (910) 721-4050 |
News Archive
Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections.
Celgene Corporation today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
La Jolla Pharmaceutical Company today announced that La Jolla and Adamis Pharmaceuticals Corporation have agreed to terminate their merger agreement relating to the proposed merger of the two companies.
Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system's action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells ("Galectins," Chapter 7, Wiley, 2008).
For people with Down syndrome, news from Elixirgen, LLC may brighten their day. The biotechnology company, located in the Science + Technology Park at Johns Hopkins, has outlined one of the best potential therapies yet for people with Down syndrome and other chromosome disorders in a paper entitled, "Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures," published in the journal DNA Research.
› Verified 8 days ago
Dr. Emily Grace Lineberger, CNM, WHNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 584 Hospital Dr, Suite B, Bolivia, NC 28422 Phone: 630-740-6161 | |
Denise Anna-marie Davies, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 584 Hospital Dr Ne Unit B, Bolivia, NC 28422 Phone: 910-721-4050 Fax: 910-721-4051 | |
Kiya Nichole Fox, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 584 Hospital Dr Ne Unit B, Bolivia, NC 28422 Phone: 910-721-4050 Fax: 910-721-4051 |